Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / NVCR - Buy NovoCure: The First Mover In The New Modality In Cancer Treatment


NVCR - Buy NovoCure: The First Mover In The New Modality In Cancer Treatment

NovoCure (NVCR) is an innovative medical device company that is developing the fourth modality in cancer treatment. I rate NovoCure a buy. As the lead and only developer of Tumor Treating Field (TTField), the company has the potential to gain a significant share of the vast cancer treatment market. Even though the valuation of NovoCure shares seems rich, I think the market does not fully appreciate the potential of this treatment modality. Hence, investing in NovoCure at current share price can produce multi-bagger returns in five to ten years. This article intends to

Read more ...

Stock Information

Company Name: NovoCure Limited
Stock Symbol: NVCR
Market: NASDAQ
Website: novocure.com

Menu

NVCR NVCR Quote NVCR Short NVCR News NVCR Articles NVCR Message Board
Get NVCR Alerts

News, Short Squeeze, Breakout and More Instantly...